Citations

Clear

959 citation(s) found for "Service, F J".

Hypertrophic cardiomyopathy management: a systematic review of the clinical practice guidelines and recommendations
Sanghvi, Mihir M. , Dhall, Eamon , Chahal, C. Anwar A. , Savvatis, Konstantinos , Ricci, Fabrizio , Munroe, Patricia B. , Petersen, Steffen E. , Aung, Nay , Khanji, Mohammed Y , Chahal, Choudhary Anwar A , Savvatis, Konstantinos , Ricci, Fabrizio , Munroe, Patricia B , Petersen, Steffen E , Aung, Nay , Khanji, Mohammed Yunus , O’Mahony, Constantinos , Mohiddin, Saidi , Ricci, Fabrizio

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | December 31, 2024 | Volume: 11 | Issue: 7 | Pages: 919-933

10.1093/ehjqcco/qcae117 | PMID 39749832 Get It

Abstract Aims In light of recent advances in imaging techniques, molecular understanding and therapeutic options in hypertrophic cardiomyopathy (HCM), we performed a systematic review of current guidelines for the diagnosis and management of HCM in order to identify consensus and discrepant areas in the clinical practice guidelines. Methods and results We systematically reviewed the English language guidelines and recommendations for the management of HCM in adults. MEDLINE and EMBASE databases were searched for guidelines published in the last 10 years. Following a systematic search, three guidelines on the diagnosis and management of HCM were identified, all of which were robustly developed (AGREE rigour of development score ≥50%). These guidelines were authored by the major European (European Society of Cardiology; 2023), American (American Heart Association /American College of Cardiology/American Medical Society for Sports Medicine /Heart Rhythm Society/Pediatric and Congenital Electrophysiology Society/Society for Cardiovascular Magnetic Resonance; 2024), and Japanese [Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS); 2018] cardiovascular societies. There was broad consensus on echocardiographic recommendations, the medical and invasive management of HCM, the application of genetic testing and family screening, and exercise and reproductive recommendations in HCM. There were areas of variability in the definition and diagnostic criteria for HCM, cardiovascular magnetic resonance imaging recommendations, and assessment of sudden cardiac death (SCD) risk and prevention strategies. Due to the JCS/JHFS guidelines being older, there are no recommendations on the use of cardiac myosin ATPase inhibitors. Conclusion Contemporary guidelines for HCM achieve consensus across a broad range of criteria and recommendations concerning diagnosis and management. However, variations in the approach towards risk assessment for SCD exist between the guidelines. There are also more subtle differences concerning diagnostic criteria and the utility of late gadolinium enhancement for risk stratification, which will likely evolve as the evidence-base broadens.
Association that Neuroimaging and Clinical Measures Have with Change in Arm Impairment in a Phase 3 Stroke Recovery Trial
Schwarz, Anne , Feldman, Marc D., Le, Vu , Dawson, Jesse, Francisco, Gerard E., Wolf, Steven L., Dixit, Anand, Alexander, Jen , Ali, Rushna , Brown, Benjamin L. , Feng, Wuwei , DeMark, Lou , Hochberg, Leigh R. , Majid, Arshad , O’Dell, Michael W. , Redgrave, Jessica, Cramer, Steven C. , Feng, Wuwei , Cramer, Steven C , Dawson, Jesse , Liu, Charles Y. , Francisco, Gerard E. , Kautz, Steven A. , Turner, Duncan L. , Kimberley, Teresa Jacobson

Mayo Clinic

Annals of Neurology | December 16, 2024 | Volume: 97 | Issue: 4 | Pages: 709-719

10.1002/ana.27156 | PMID 39676623 Get It

ObjectiveVagus nerve stimulation (VNS) paired with rehabilitation therapy improved motor status compared to rehabilitation alone in the phase III VNS‐REHAB stroke trial, but treatment response was variable and not associated with any clinical measures acquired at baseline, such as age or side of paresis. We hypothesized that neuroimaging measures would be associated with treatment‐related gains, examining performance of regional injury measures versus global brain health measures in parallel with clinical measures.MethodsBaseline magnetic resonance imaging (MRI) scans in the VNS‐REHAB trial were used to derive regional injury measures (extent of injury to corticospinal tract, the primary regional measure; plus extent of injury to precentral gyrus and postcentral gyrus; lesion volume; and lesion topography) and global brain health measures (degree of white matter hyperintensities, the primary global brain measure; plus volumes of cerebrospinal fluid, cortical gray matter, white matter, each thalamus, and total brain). Eight clinical measures assessed at baseline were also evaluated (treatment group, age, race, gender, paretic side, pre‐stroke dominant hand, time since stroke, and baseline Fugl‐Meyer upper extremity score). Bivariate analyses compared each measure with the primary trial end point (change in Fugl‐Meyer upper extremity score from baseline to end of 6 weeks of treatment) across all subjects, with secondary analyses examining trial groups separately.ResultsMRIs were available from 80 patients (age = 59.8 ± 9.5 years, 29 women). Across all patients, less white matter hyperintensities (r = −0.25, p = 0.028) at baseline was associated with larger Fugl‐Meyer score change. In the VNS group, less white matter hyperintensities (r = −0.37, p = 0.018) and larger ipsilesional thalamus volume (r = 0.33, p = 0.046) were each associated with larger Fugl‐Meyer score change. Analysis of covariance (ANCOVA) analyses tested the interaction that each baseline measure had with treatment group and found that the model examining white matter hyperintensities had a significant interaction term, indicating 2.3 less change in Fugl‐Meyer Upper Extremity (FM‐UE) points in the VNS group relative to the control group for each point increase in modified Fazekas scale.InterpretationNeuroimaging measures are associated with extent of gains on the primary endpoint of a phase III stroke recovery trial. Among the neuroimaging measures examined, a measure of global brain health (extent of white matter hyperintensities) was better at explaining the change in arm impairment as compared with measures of regional injury; this was true when examining all study subjects as well as only those in the VNS group and is consistent with the global mechanism of action that VNS has throughout the cerebrum. Future studies can evaluate additional measures that further predict response to VNS therapy. The current findings suggest that individual patient neuroimaging results may be useful for a personalized medicine approach to stroke recovery therapeutics. ANN NEUROL 2025;97:709–719
Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations
Sorella, Anna, Galanti, Kristian , Iezzi, Lorena , Gallina, Sabina , Mohammed, Selma F. , Sekhri, Neha, Akhtar, Mohammed , Prasad, Sanjay, Chahal, Choudhary Anwar Ahmed, Ricci, Fabrizio , Khanji, Mohammed Y , Khanji, Mohammed Yunus , Ricci, Fabrizio , Chahal, Choudhary Anwar Ahmed

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | December 15, 2024 | Volume: 11 | Issue: 2 | Pages: 206-222

10.1093/ehjqcco/qcae109 | PMID 39674807 Get It

Abstract Dilated cardiomyopathy (DCM) is extensively discussed in numerous expert consensus documents and international guidelines, with differing recommendations. To support clinicians in daily practice and decision-making, we conducted a systematic review of key guidelines and recommendations concerning the diagnosis and clinical management of DCM. Our research encompassed MEDLINE and EMBASE databases for relevant articles published, as well as the websites of relevant scientific societies. We identified two guidelines and one scientific statement that met stringent criteria, thereby qualifying them for detailed systematic analysis. Our review revealed consensus on several key aspects: the definition of DCM, the use of B-type natriuretic peptides and high-sensitivity troponin in laboratory testing, the essential role of multimodality cardiovascular imaging for initial diagnosis, genetic counselling, and the management of advanced disease. Nonetheless, notable areas of variation included the formation of multidisciplinary management teams, the role of cascade genetic testing, pathways for arrhythmic risk stratification, and the criteria for prophylactic defibrillator implantation. Significant evidence gaps persist, particularly regarding the clinical trajectory of genetic, non-genetic and gene-elusive forms of DCM, the use of cardiovascular magnetic resonance in phenotype-negative family members with genotype-positive probands, and the development of potential aetiology-oriented therapies. Addressing these gaps could enhance clinical outcomes and inform future research directions and guideline development.
The ASPEN Rhoads Research Foundation: Supporting and advancing clinical nutrition research
Winkler, Marion F. , McMahon, M. Molly , Spangenburg, Michelle, Compher, Charlene , Winkler, Marion F , Compher, Charlene , Tappenden, Kelly A

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | December 5, 2024 | Volume: 49 | Issue: 1 | Pages: 10-17

10.1002/jpen.2707 | PMID 39638749 Get It

Abstract The vision of the ASPEN Rhoads Research Foundation is to promote innovation and research discovery to improve nutrition care and health. The Foundation was launched in 1993, incorporated in 2002, and established as a nonprofit 501(c)(3) organization in 2007. On the occasion of American Society for Parenteral and Enteral Nutrition (ASPEN)'s 50th anniversary, this article examines the creation of the Foundation, the state of clinical nutrition research funding, the Foundation's philanthropic mission, and the return on investment of Foundation grant support. To date, 114 investigators have received 2.78 million dollars in funding. The article examines the success of ASPEN research programs and Foundation grant support in career development, leadership, and mentorship. It is important to document a historical account of the ASPEN Rhoads Research Foundation and encourage innovation and discovery and ongoing financial support.
Abstract 4147050: Genetic Insights into Arrhythmogenic Mitral Valve Prolapse – A Case-Control Study from UK Biobank and NIH All of Us
Dabbagh, Ghaith Sharaf , Hesse, Kerrick , Agnihotri, Ruchi, Kaur, Gurpreet , Gurumoorthi, Manasa, Mitchell, Saige M. , Pargament, Robert, Malik, Adnan , Schuler, Brian, Obeng‐Gyimah, Edmond, Ricci, Fabrizio , Landstrom, Andrew P. , Landstrom, Andrew P , Agnihotri, Ruchi, Shah, Ravi V. , Asatryan, Babken , Galanti, Kristian , Wolfe, Rachel, Malik, Adnan, Munroe, Patricia B. , Somers, Virend K. , Ricci, Fabrizio , Khanji, Mohammed Y , Chahal, C. Anwar A.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4147050 Get It

Background: Mitral valve prolapse (MVP) is a common valvular abnormality. Observational studies demonstrate an association between MVP and increased risk of sudden cardiac death from ventricular arrhythmias, coined arrhythmogenic MVP. A genetic component has been postulated but remains under-investigated. Hypothesis: Predicted deleterious variants in Mendelian cardiomyopathy and arrhythmia genes are more frequent in arrhythmogenic MVP (aMVP) compared to non-arrhythmogenic MVP. Aims: To comprehensively phenotype and genotype a single-center aMVP cohort and compare to non-aMVP from two large population-based cohorts and investigate their clinical outcomes. Methods: The aMVP cohort included 46 prospectively enrolled patients from a regional referral center for inherited cardiovascular disease and had undergone multi-modality imaging and clinical gene panel testing. The non-aMVP comparator cohorts included 453 participants from the UK Biobank (UKBB), a prospective cohort of 500,000 UK residents, and 1,418 participants from the National Institutes of Health (NIH) All of Us (AoU), a prospective cohort of 450,000 USA participants. Gene variants were annotated in ANNOVAR. Participants with and without pathogenic/likely pathogenic (P/LP) variants reported on ClinVar with ≥2-star level of evidence were considered genotype positive (G+) and negative (G-) respectively. Results: The demographics for aMVP (age 61.2 ± 12.8 years, 56.5% female) and non-aMVP (UKBB: age 59.8 ± 7.3 years, 50.7% female and AoU: age 65.3 ± 13.4 years, 76.2% female) were comparable. G+ participants were more prevalent in the aMVP cohort 10/46 (21.7%) versus non-aMVP in the UKBB 8/453 (1.8%) and in the AoU 21/1418 (1.5%); p<0.001. The most frequently implicated gene in aMVP was TTN . Of 46 in aMVP cohort, 33 (71%) underwent CMR. G+ participants had a higher frequency of late gadolinium enhancement [6/6 (100%) vs. 14/27 (51.8%), p<0.001] and wall motion abnormalities [3/6 (50%) vs. 1/27 (3.7%), p<0.001] compared to G- participants. The aMVP cohort had significantly more implantable cardioverter defibrillator (ICD) implants compared to non-aMVP cohort [5/46 (10.9%) vs. 1/453 in UKBB (0.2%), p<0.001]. G+ aMVP cohort showed a trend for developing heart failure and ICD implants compared to G- aMVP . Conclusion: P/LP variants in cardiomyopathy and arrhythmia genes are more prevalent in aMVP participants compared to non-aMVP participants. This could be a hitherto unrecognized effect modifier predicting aMVP .
Abstract 4145199: Prevalence and Prognostic Implications of Sleep Disordered Breathing in Hypertrophic Cardiomyopathy
Venkataraman, Shreyas , Deshmukh, Abhishek , Siontis, Konstantinos, Konecny, Thomas, Geske, Jeffrey B. , Geske, Jeffrey B , Karim, Shahid , Chahal, C. Anwar A. , Mansukhani, Meghna P. , Khanji, Mohammed Y , Petersen, Steffen E. , Somers, Virend K.

Mayo Clinic

Circulation | November 14, 2024 | Volume: 150 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.150.suppl_1.4145199 Get It

Background: Sleep disordered breathing (SDB) is frequently observed in patients with cardiovascular disease, and is associated with intermittent hypoxia, sympathetic activation, oxidative stress, and endothelial dysfunction, all of which may facilitate the development and progression of cardiovascular disease. Objectives: We sought to determine the prevalence, subtypes, and clinical implications of comorbid SDB in patients with hypertrophic cardiomyopathy (HCM). Methods: In this prospective observational study, patients with HCM without prior diagnosis of SDB were recruited to undergo inpatient polysomnography between May 1 st 2018 and October 31 st 2022. Electrocardiographic and echocardiographic parameters, cardiac biomarkers, and symptoms were comparatively assessed in patients with and without comorbid SDB. Patients were assessed for the development of major adverse cardiovascular events (MACE) during follow-up (median 29, range 3-57 months). Results Among 154 participants, 91 (59.1%) were diagnosed with SDB of whom 38 (41.8%) had mild, 22 (24.2%) moderate, 18 (19.8%) severe obstructive sleep apnea, and 13 (14.3%) had central sleep apnea. SDB was associated with greater left ventricular mass (median [IQR]) (128 [107, 161] vs. 109 [96, 134] g/m 2 , p =0.034) and E/e’ ratio (12.5 [10, 15] vs. 10.0 [8.3, 14.5], p =0.039). Patients with HCM over the age of 50 years, with body mass index ≥ 30kg/m 2 , who described their sleep as “poor” were at particularly high risk of having comorbid SDB, as were those who were diabetic, hypertensive, or described greater exertional limitation (NYHA Class ≥II 53% vs. 27%, p =0.005). Importantly, subjects with SDB had elevated baseline Troponin T levels (14 ng/L vs 11 ng/L, p =0.030), and further substantial overnight troponin increases following untreated apneic sleep (2.1ng/L vs 0.2ng/L, p =0.009). Finally, patients with comorbid SDB experienced a significantly higher proportion of incident adverse cardiovascular events (MACE hazard ratio 5.3, 95% CI, 1.6, 17.2, p =0.006) than those without SDB. Conclusions: We report a particularly high burden of previously undiagnosed SDB in patients with HCM, particularly in older, heavier, male patients. Undiagnosed SDB in HCM is not benign and is associated with symptom progression, comorbidity, and a poorer prognosis, particularly in the case of central sleep apnea. These important new findings provide rationale for heightened vigilance and routine screening for SDB in patients with HCM.
Burden of Hyperlipidemia, Cardiovascular Mortality, and COVID‐19: A Retrospective‐Cohort Analysis of US Data
Ibrahim, Ramzi , Sainbayar, Enkhtsogt , Olson, April, Khanji, Mohammed Y , Lee, Justin Z. , Somers, Virend K. , Wenger, Christopher, Chahal, C. Anwar A. , BMBCh, Mamas A. Mamas, Mamas, Mamas A. , Ibrahim, Ramzi , Sainbayar, Enkhtsogt , Khanji, Mohammed Yunus , Deshmukh, Abhishek J , Somers, Virend K. , Chahal, Choudhary Anwar A , Mamas, Mamas , Pham, Hoang Nhat , Singh, Amitoj

Mayo Clinic

Journal of the American Heart Association | November 11, 2024 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/jaha.124.037381 | PMID 39526321 Get It

Background Hyperlipidemia is a major cardiovascular disease (CVD) risk factor, but there are limited data on its mortality trends in CVD over time. We assessed annual hyperlipidemia‐related CVD mortality trends in the United States, including the COVID‐19 pandemic's impact. Methods and Results Mortality data were obtained from the Centers for Disease Control and Prevention repository between 1999 and 2020 among patients ≥15 years old, using International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes for hyperlipidemia (E78.0–E78.5) and CVD (I00–I99). Age‐adjusted mortality rates (AAMRs) per 1 000 000 population were standardized to the 2000 US population. Log‐linear regression models were used to evaluate mortality shifts. Average annual percentage change from 1999 to 2019 was used to project 2020 AAMRs, estimating pandemic‐attributed excess deaths. From 1999 to 2020, 483 155 hyperlipidemia‐related CVD deaths occurred. Despite a general CVD mortality decline, hyperlipidemia‐related CVD AAMRs rose from 36.33 in 1999 to 99.77 in 2019. Ischemic heart diseases (AAMR 49.39) were the leading cause, whereas hypertension had the highest mortality increase (average annual percentage change +10.23%). Mortality rates were higher in men (AAMR 104.87) and non‐Hispanic (AAMR 82.49), and rural populations (AAMR 89.98). Highest mortality was observed in Black populations (AAMR 84.35), those ≥75 years old (AAMR 646.45), and Western US regions (AAMR 96.88). During the first pandemic year, deaths exceeded projections by 10.55%, with notable increases among ages 35 to 75 (14.23%), Hispanic (17.96%), Black (14.82%), and urban (11.68%) groups. Conclusions Hyperlipidemia‐related CVD mortality has risen over the past 2 decades, further heightened by the COVID‐19 pandemic, with higher impact on men, Black Americans, the older population, and rural residents. Further study is needed to understand contributing factors and mitigate disparities.
ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten
Jacobs, Michael R. , Good, Caryn E., Abdelhamed, Ayman M., Mack, Andrew R , Bethel, Christopher R. , Marshall, Steven H. , Hujer, Andrea M. , Hujer, Kristine M., Patel, Robin , Fowler, Vance G., Rhoads, Daniel D. , Six, David A. , Papp‐Wallace, Krisztina M. , van Duin, David , Rhoads, Daniel D , Six, David A , Moeck, Greg , Uehara, Tsuyoshi , Papp-Wallace, Krisztina M , Bonomo, Robert A , Patel, Robin , Hujer, Kristine M., Fowler, Vance G. , Uehara, Tsuyoshi , Bonomo, Robert A.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | October 30, 2024 | Volume: 68 | Issue: 12 | Pages: No page available

10.1128/aac.01127-24 | PMID 39475259 Get It

ABSTRACT Ledaborbactam (formerly VNRX-5236), a bicyclic boronate β-lactamase inhibitor with activity against class A, C, and D β-lactamases, is under development as an orally bioavailable etzadroxil prodrug (VNRX-7145) in combination with ceftibuten for the treatment of urinary tract infections. At ceftibuten breakpoints of ≤1 mg/L (EUCAST) and ≤8 mg/L (CLSI), 92.5% and 99.0%, respectively, of 200 carbapenem-resistant Klebsiella pneumoniae isolates, predominantly K. pneumoniae carbapenemase producing, were susceptible to ceftibuten-ledaborbactam (ledaborbactam tested at a fixed concentration of 4 mg/L) compared to 4.5% and 30.5%, respectively, to ceftibuten alone.
Barriers to Perinatal Care among Immigrant and Migrant Women in Southeast Minnesota
Reckhow, Jensen , Riggan, Kirsten A. , Bruetzman, Emily, Orellana, Minerva , Low, Stephanie, Tobah, Yvonne Butler , Rivera‐Chiauzzi, Enid Y. , Allyse, Megan , Torbenson, Vanessa E. , Rivera-Chiauzzi, Enid Y , Allyse, Megan A , Orellana, Minerva A , Riggan, Kirsten A

Mayo Clinic

Women's Health Reports | October 29, 2024 | Volume: 5 | Issue: 1 | Pages: 842-848

10.1089/whr.2024.0108 Get It

Reply
England, Bryant R. , Brooks, Rebecca , Mikuls, Ted R. , Brooks, Rebecca T , Mikuls, Ted R , England, Bryant R

Mayo Clinic

Arthritis & Rheumatology | October 28, 2024 | Volume: 77 | Issue: 5 | Pages: 627-627

10.1002/art.43048 | PMID 39465496 Get It